A Phase 4, Postmarketing Study Evaluating The Impact Of Prevnar 13 (Trademark)(13-valent Pneumococcal Conjugate Vaccine; 13vpnc) In Reducing Acute Otitis Media And Nasopharyngeal Colonization Caused By Streptococcus Pneumoniae In Healthy Children
Phase of Trial: Phase IV
Latest Information Update: 03 Mar 2017
At a glance
- Drugs Pneumococcal 13-valent CRM197 vaccine conjugate (Primary)
- Indications Otitis media; Pneumococcal infections
- Focus Therapeutic Use
- Sponsors Pfizer
- 26 Apr 2016 Status changed from active, no longer recruiting to completed.
- 04 Jun 2015 Planned End Date changed from 1 Sep 2015 to 1 Mar 2016 as per ClinicalTrials.gov record.
- 04 Jun 2015 Planned primary completion date changed from 1 Sep 2015 to 1 Mar 2016 as per ClinicalTrials.gov record.